Form 4: ClearPoint Neuro CEO Sells Shares Following Restricted Stock Unit Vesting

ClearPoint Neuro, Inc. CEO and President Joseph Burnett sold 21,247 shares of common stock on June 9, 2025, at a weighted average price of $13.29 per share, as part of a net share settlement of vested restricted stock units.

Summary

• Joseph Burnett, the CEO and President, and a Director of ClearPoint Neuro, Inc. (CLPT), reported a transaction involving company common stock.
• On June 9, 2025, Mr. Burnett sold 21,247 shares of ClearPoint Neuro, Inc. common stock.
• The shares were sold at a weighted average price of $13.29 per share, with individual sales prices ranging from $13.20 to $13.51.
• This sale was incident to the net share settlement of 21,247 restricted stock units (RSUs) that vested on March 6, 2025, which were originally granted on March 6, 2023.
• Following this transaction, Joseph Burnett directly beneficially owns 25,363 shares of common stock.
• Additionally, Mr. Burnett indirectly beneficially owns 243,522 shares through the Joseph M. Burnett Trust dated October 20, 2022, where he serves as trustee.

Sentiment

Score: 5

Explanation: The transaction represents a routine net share settlement of vested restricted stock units for tax purposes, rather than a discretionary sale, thus having a neutral sentiment.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This document is an insider trading report (Form 4) and does not provide information relevant to broader industry trends or competitor analysis. It solely details a specific transaction by a company executive.

Related Party Transactions

• Joseph M. Burnett indirectly owns 243,522 shares through the Joseph M. Burnett Trust dated 10/20/2022, where he serves as trustee.

Stakeholder Impact

• Shareholders may note the insider sale, but its nature as a net share settlement for RSU vesting typically mitigates concerns about management's confidence in the company's future.

Key Dates

Recommendation

Keywords

ClearPoint Neuro, CLPT, Joseph Burnett, Form 4, Insider Trading, Stock Sale, Restricted Stock Units, RSU Vesting, Beneficial Ownership